

Vutrisiran (Amvuttra™)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DS – Maximum Days’ Supply Allowed	PU – Prior Use of Other Medication is Required
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DT – Duration of Therapy Limit	QL – Quantity Limit
BY – Diagnosis Codes Bypass Some Requirements	DX – Diagnosis Code Requirement	RX – Specific Prescription Requirement
CL – Additional Clinical Information is Required	ER – Early Refill	TD – Therapeutic Duplication
CU – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	YQ – Yearly Quantity Limit
DD – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

Vutrisiran (Amvuttra™)

POS Edits
<u>CL</u> – Additional clinical information (age, diagnosis, etc.) is required for this agent.
DX – Pharmacy claims for this agent must be submitted with an appropriate diagnosis code found at <u>THIS LINK</u> .
<u>QL</u> – This agent is limited to a maximum quantity of 1 syringe every 3 months.

Revision / Date	Implementation Date
Created POS Document / August 2022	April 2023
Formatting changes / August 2023	October 2023
<u>Added clinical authorization requirement and quantity limit, and removed POS diagnosis code requirement / June 2025</u>	<u>January 2026</u>

Vutrisiran (Amvuttra™)